Sistemas nanoparticulados como estratégia vacinal para SARS-CoV-2 DOI Creative Commons
Roberta Liberato Pagni

Опубликована: Авг. 12, 2024

The current vaccines against the novel coronavirus severe acute respiratory syndrome 2 (SARS-CoV-2) are administered systemically, and while there has been exceptional progress in vaccine development, they generally limited terms of achieving local immunity tract, which is main route SARS-CoV-2 infection.As a consequence, vaccination unable to reduce viral spread transmission, ultimately failing prevent infection.To overcome limitations systemic due emergence new variant strains, we developed subunit nasal based on receptor-binding domain (RBD) Spike protein plus adjuvant collection selected T-cell epitopes carried mucus-penetrating nanoparticle coated with mucoadhesive polymer, named Multicovax.This was assessed for long-term immunogenicity, protective efficacy, boosting capacity following primary murine model.When 3-dose regimen via instillation, Multicovax containing antigen from ancestral strain able induce response one year robust response, high neutralizing pseudovirus year, cellular being protection infection, significantly reducing load at site application lungs.As booster dose, increased antibody after each booster, induced humoral single Omicron pseudoviruses, as well response.The this study presents innovative potential higher efficacy an immunological standpoint herd creation, through generation mucosal immune potentially acting potent complementary currently available vaccines.

Язык: Английский

Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses DOI Creative Commons
David M. Morens, Jeffery K. Taubenberger, Anthony S. Fauci

и другие.

Cell Host & Microbe, Год журнала: 2023, Номер 31(1), С. 146 - 157

Опубликована: Янв. 1, 2023

Язык: Английский

Процитировано

131
Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens DOI Creative Commons
Farokh Dotiwala, Arun Kumar Upadhyay

Vaccines, Год журнала: 2023, Номер 11(10), С. 1585 - 1585

Опубликована: Окт. 12, 2023

Inducing humoral and cytotoxic mucosal immunity at the sites of pathogen entry has potential to prevent infection from getting established. This is different systemic vaccination, which protects against development symptoms. The field vaccination seen fewer technological advances compared nucleic acid subunit vaccine for injectable platforms. advent next-generation adenoviral vectors given a boost research. Basic research into mechanisms regulating innate adaptive discovery effective safe adjuvants will continue improve design. results clinical trials inhaled COVID-19 vaccines demonstrate their ability induce proliferation T cells production secreted IgA IgG antibodies locally, unlike intramuscular vaccinations. However, these immune responses par with review summarizes function respiratory mucosa-associated lymphoid tissue advantages that provide as

Язык: Английский

Процитировано

29
Gene Signature of Regulatory T Cells Isolated from Children with Selective IgA Deficiency and Common Variable Immunodeficiency DOI Creative Commons
Magdalena Rutkowska-Zapała,

Agnieszka Grabowska-Gurgul,

Marzena Lenart

и другие.

Cells, Год журнала: 2024, Номер 13(5), С. 417 - 417

Опубликована: Фев. 27, 2024

Selective IgA deficiency (SIgAD) is the most common form and variable immunodeficiency (CVID) symptomatic of predominant antibody deficiency. Despite differences in clinical picture, a similar genetic background suggested. A feature both disorders occurrence autoimmune conditions. Regulatory T cells (Tregs) are major immune cell type that maintains tolerance. As different types abnormalities Treg have been associated with primary (PID) patients, our study we aimed to analyze gene expression profiles CVID SIgAD patients compared age-matched healthy controls. The transcriptome-wide profiling was performed by microarray technology. result, analyzed visualized patterns isolated population cells. We showed at level between without autoimmunizations. Our findings suggest signatures from differ controls each other, presenting transcriptional enriched innate or Th response, respectively. autoimmunity PID down-regulation class I IFNs signaling pathways. In summary, improve understanding dysfunctions PIDs autoimmunity.

Язык: Английский

Процитировано

3
SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19? DOI
Rohan Ameratunga,

A. M. Jordan,

Klaus Lehnert

и другие.

Antiviral Research, Год журнала: 2024, Номер 227, С. 105894 - 105894

Опубликована: Апрель 25, 2024

Язык: Английский

Процитировано

2
Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19 DOI
Rohan Ameratunga, Emily Mears, Euphemia Leung

и другие.

Clinical & Experimental Immunology, Год журнала: 2023, Номер 214(3), С. 289 - 295

Опубликована: Авг. 11, 2023

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for disease of 2019 (COVID-19), has caused havoc around world. While several COVID-19 vaccines and drugs have been authorized use, these antiviral remain beyond reach most low- middle-income countries. Rapid viral evolution is reducing efficacy monoclonal antibodies contributing to deaths some fully vaccinated persons. Others with normal immunity may chosen not be at risk if they contract infection. Vaccines protect immunodeficient patients from SARS-CoV-2, who are also increased chronic infection, a dangerous stalemate between suboptimal immune response. Intra-host could rapidly lead selection dominance vaccine antibody-resistant clades SARS-CoV-2. There thus an urgent need develop new treatments COVID-19. The NZACE2-Pātari project, comprising modified soluble angiotensin-converting enzyme (ACE2) molecules, seeks intercept block SARS-CoV-2 infection mucosa. In vitro data presented here show that wild-type ACE2 molecules retain ability effectively Spike (S) glycoprotein variants including ancestral Wuhan, delta (B.1.617.2) omicron (B.1.1.529) strains. This therapeutic strategy prove effective implemented early during nasal phase act synergistically other such as Paxlovid further mitigate severity.

Язык: Английский

Процитировано

4
An overview of early genetic predictors of IgA deficiency DOI
Saba Fekrvand, Hassan Abolhassani, Nima Rezaei

и другие.

Expert Review of Molecular Diagnostics, Год журнала: 2024, Номер 24(8), С. 715 - 727

Опубликована: Авг. 1, 2024

Introduction Inborn errors of immunity (IEIs) refer to a heterogeneous category diseases with defects in the number and/or function components immune system. Immunoglobulin A (IgA) deficiency is most prevalent IEI characterized by low serum level IgA and normal levels IgG IgM. Most individuals are asymptomatic only identified through routine laboratory tests. Others may experience wide range clinical features including mucosal infections, allergies, malignancies as important features. multi-complex disease, exact pathogenesis it still unknown.

Язык: Английский

Процитировано

0
Increased Prevalence of Attention Deficit Hyperactivity Disorder in Individuals with Selective Immunoglobulin A Deficiency: A Nationwide Case–Control Study DOI Open Access
Eugene Merzon,

Rosemary Farag,

Shai Ashkenazi

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(20), С. 6075 - 6075

Опубликована: Окт. 12, 2024

: Selective Immunoglobulin A Deficiency (SIgAD) is one of the most prevalent immunodeficiencies, characterized by an increased risk mucosal infections. Attention deficit hyperactivity disorder (ADHD) among common neurodevelopmental disorders and associated with significantly higher rates various infectious diseases, white blood cell abnormalities, considerable morbidity. This study aimed to evaluate prevalence ADHD patients SIgAD.

Язык: Английский

Процитировано

0
Sistemas nanoparticulados como estratégia vacinal para SARS-CoV-2 DOI Creative Commons
Roberta Liberato Pagni

Опубликована: Авг. 12, 2024

The current vaccines against the novel coronavirus severe acute respiratory syndrome 2 (SARS-CoV-2) are administered systemically, and while there has been exceptional progress in vaccine development, they generally limited terms of achieving local immunity tract, which is main route SARS-CoV-2 infection.As a consequence, vaccination unable to reduce viral spread transmission, ultimately failing prevent infection.To overcome limitations systemic due emergence new variant strains, we developed subunit nasal based on receptor-binding domain (RBD) Spike protein plus adjuvant collection selected T-cell epitopes carried mucus-penetrating nanoparticle coated with mucoadhesive polymer, named Multicovax.This was assessed for long-term immunogenicity, protective efficacy, boosting capacity following primary murine model.When 3-dose regimen via instillation, Multicovax containing antigen from ancestral strain able induce response one year robust response, high neutralizing pseudovirus year, cellular being protection infection, significantly reducing load at site application lungs.As booster dose, increased antibody after each booster, induced humoral single Omicron pseudoviruses, as well response.The this study presents innovative potential higher efficacy an immunological standpoint herd creation, through generation mucosal immune potentially acting potent complementary currently available vaccines.

Язык: Английский

Процитировано

0